1. Home
  2. YHC vs NEUP Comparison

YHC vs NEUP Comparison

Compare YHC & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LQR House Inc.

YHC

LQR House Inc.

HOLD

Current Price

$0.92

Market Cap

21.0M

ML Signal

HOLD

NEUP

Neuphoria Therapeutics Inc.

HOLD

Current Price

$4.01

Market Cap

21.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
YHC
NEUP
Founded
2021
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
21.0M
21.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
YHC
NEUP
Price
$0.92
$4.01
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$21.00
AVG Volume (30 Days)
181.6K
33.0K
Earning Date
11-14-2025
02-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,103,341.00
$15,649,448.00
Revenue This Year
$69.97
N/A
Revenue Next Year
$403.29
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.68
$3.65
52 Week High
$98.00
$21.40

Technical Indicators

Market Signals
Indicator
YHC
NEUP
Relative Strength Index (RSI) 49.51 45.06
Support Level $0.80 $3.98
Resistance Level $0.95 $4.11
Average True Range (ATR) 0.07 0.12
MACD 0.00 0.01
Stochastic Oscillator 56.74 19.35

Price Performance

Historical Comparison
YHC
NEUP

About YHC LQR House Inc.

LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.

About NEUP Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

Share on Social Networks: